Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine

被引：11

作者：

Deininger, Kimberly M. ^{[1
]}

Page, Robert L., II ^{[2
]}

Lee, Yee Ming ^{[2
]}

Kauffman, Yardlee S. ^{[3
]}

Johnson, Samuel G. ^{[4
,5
]}

Oreschak, Kris ^{[1
]}

Aquilante, Christina L. ^{[1
]}

机构：

[1] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA

[2] Univ Colorado, Dept Clin Pharm, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA

[3] Univ Sci, Dept Pharm Practice & Pharm Adm, Philadelphia, PA USA

[4] Board Pharm Specialties, Washington, DC USA

[5] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA

来源：

PERSONALIZED MEDICINE | 2019年 / 16卷 / 02期

关键词：

cardiologist; cardiology; clinical implementation; personalized medicine; pharmacogenetic; pharmacogenomic; qualitative research; IMPLEMENTATION CONSORTIUM GUIDELINES; CLINICAL UTILITY; CYP2C19; GENOTYPE; CPIC GUIDELINES; PROFESSIONALS; PHARMACISTS; PERCEPTIONS; ATTITUDES; THERAPY; VIEWS;

D O I：

10.2217/pme-2018-0099

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: To evaluate factors influencing cardiologists' perspectives about pharmacogenomic (PGx) testing in clinical practice. Patients & methods: Semistructured interviews with practicing cardiologists were qualitatively analyzed to identify common themes. Results: Five themes were identified among 16 cardiologists from four specialties (n=5 general cardiology, n=3 electrophysiology, n=2 adult congenital and n=6 heart failure/transplant): cardiologists' knowledge and needs, perceived clinical validity and utility of PGx testing, dissemination and management of PGx results, patient-related considerations and incidental findings. Conclusion: Lack of evidence was considered by many cardiologists to be a major barrier hindering the use of PGx testing. However, they would consider adopting PGx if they were provided additional education, ongoing support and evidence supporting the clinical utility of PGx testing in cardiovascular medicine.

引用

页码：123 / 132

页数：10

共 32 条

[11] Views of Genetics Health Professionals on the Return of Genomic Results [J].

Grove, Megan E. ;

Wolpert, Maya N. ;

Cho, Mildred K. ;

Lee, Sandra Soo-Jin ;

Ormond, Kelly E. .

JOURNAL OF GENETIC COUNSELING, 2014, 23 (04) :531-538

[12] Primary care physicians' knowledge of and experience with pharmacogenetic testing [J].

Haga, S. B. ;

Burke, W. ;

Ginsburg, G. S. ;

Mills, R. ;

Agans, R. .

CLINICAL GENETICS, 2012, 82 (04) :388-394

[13] Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing [J].

Haga, S. B. ;

O'Daniel, J. M. ;

Tindall, G. M. ;

Mills, R. ;

Lipkus, I. M. ;

Agans, R. .

CLINICAL GENETICS, 2012, 82 (02) :115-120

[14] Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings [J].

Haga, Susanne B. ;

Tindall, Genevieve ;

O'Daniel, Julianne M. .

GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (01) :21-24

[15] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update [J].

Johnson, J. A. ;

Caudle, K. E. ;

Gong, L. ;

Whirl-Carrillo, M. ;

Stein, C. M. ;

Scott, S. A. ;

Lee, M. T. ;

Gage, B. F. ;

Kimmel, S. E. ;

Perera, M. A. ;

Anderson, J. L. ;

Pirmohamed, M. ;

Klein, T. E. ;

Limdi, N. A. ;

Cavallari, L. H. ;

Wadelius, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (03) :397-404

[16] Developing Pharmacogenomic Reports: Insights from Patients and Clinicians [J].

Jones, Laney K. ;

Rahm, Alanna Kulchak ;

Gionfriddo, Michael R. ;

Williams, Janet L. ;

Fan, Audrey L. ;

Pulk, Rebecca A. ;

Wright, Eric A. ;

Williams, Marc S. .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2018, 11 (03) :289-295

[17] What Is Clinical Utility and Why Should We Care? [J].

Lesko, L. J. ;

Zineh, I. ;

Huang, S-M .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) :729-733

[18] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [J].

Moriyama, B. ;

Obeng, A. Owusu ;

Barbarino, J. ;

Penzak, S. R. ;

Henning, S. A. ;

Scott, S. A. ;

Agundez, J. A. G. ;

Wingard, J. R. ;

McLeod, H. L. ;

Klein, T. E. ;

Cross, S. J. ;

Caudle, K. E. ;

Walsh, T. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) :45-51

[19] Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial [J].

Notarangelo, Francesca Maria ;

Maglietta, Giuseppe ;

Bevilacqua, Paola ;

Cereda, Marco ;

Merlini, Piera Angelica ;

Villani, Giovanni Quinto ;

Moruzzi, Paolo ;

Patrizi, Giampiero ;

Tagliazucchi, Guidantonio Malagolia ;

Crocamo, Antonio ;

Guidorossi, Angela ;

Pigazzani, Filippo ;

Nicosia, Elisa ;

Paoli, Giorgia ;

Bianchessi, Marco ;

Comelli, Mario Angelo ;

Caminiti, Caterina ;

Ardissino, Diego .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (17) :1869-1877

[20] Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey [J].

Obeng, Aniwaa Owusu ;

Fei, Kezhen ;

Levy, Kenneth D. ;

Elsey, Amanda R. ;

Pollin, Toni I. ;

Ramirez, Andrea H. ;

Weitzel, Kristin W. ;

Horowitz, Carol R. .

JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (03)

← 1 2 3 4 →